首页> 外文期刊>BMC Pulmonary Medicine >How does the EQ-5D-5L perform in asthma patients compared with an asthma-specific quality of life questionnaire?
【24h】

How does the EQ-5D-5L perform in asthma patients compared with an asthma-specific quality of life questionnaire?

机译:哮喘患者的EQ-5D-5L如何与哮喘特异性的生活质量问卷?

获取原文
           

摘要

Asthma patients experience impairments in health-related quality of life (HRQL). Interventions are available to improve HRQL. EQ-5D-5L is a common generic tool used to evaluate health interventions. However, there is debate over whether the use of this measure is adequate in asthma patients. We used data from 371 asthma patients participating in a pulmonary rehabilitation (PR) program from the EPRA randomized controlled trial. We used four time points: T0 randomization, T1 start PR, T2 end PR, T3 3 months follow-up. We calculated floor and ceiling effects, intra-class correlation (ICC), Cohen’s d, and regression analysis to measure the sensitivity to changes of EQ-5D-5?L (EQ-5D index and Visual Analog Scale (VAS)) and the disease-specific Asthma Quality of Life Questionnaire (AQLQ). Furthermore, we estimated the minimally important difference (MID). Based on the Asthma Control Test (ACT) scores, we defined three groups: 1. ACT-A (ACT?19) controlled asthma, 2. ACT-B (14??ACT≤19) not well-controlled asthma, and 3. ACT-C (ACT≤14) very poorly controlled asthma. Only the EQ-5D index showed ceiling effects at T2 and T3 (32%). ICC (between T0 and T1) was moderate or good for all measures. Cohen’s d at T2 and T3 was better at differentiating between ACT-A and ACT-B than between ACT-B and ACT-C. The EQ-5D index showed moderate effect sizes (0.63–0.75), while AQLQ showed large effect sizes (0.74–1,48). VAS was responsive to pronounced positive and negative ACT changes in every period, and AQLQ mostly to the positive changes, whereas the EQ-5D index was less responsive. We estimated a MID of 0.08 for the EQ-5D index, 12.3 for VAS, and 0.65 for AQLQ. All presented HRQL tools had good discriminatory power and good reliability. However, EQ-5D-5?L did not react very sensitively to small changes in asthma control. Therefore, we would suggest using supplementary measures in addition to EQ-5D-5?L to evaluate asthma-specific interventions more comprehensively. German Clinical Trial Register, DRKS00007740 (date of registration: 05/15/2015), https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00007740. The registration took place prospectively.
机译:哮喘患者体验(HRQL)的生命健康相关的质量损伤。干预措施可以改善HRQL。 EQ-5D-5L是用于评价健康干预常见的通用工具。但是,在使用这种措施是否是在哮喘患者充分辩论。我们使用来自371名参与从EPRA随机对照试验肺康复(PR)程序哮喘患者的数据。我们用四个时间点:T0随机,T1开始PR,T2结束PR,T33个月跟进。我们计算地板和天花板的影响,组内相关(ICC),科恩的d和回归分析,以测量到EQ-5D-5'L(EQ-5D指数和视觉模拟量表(VAS))的变化的灵敏度和疾病特异性哮喘生活质量问卷(AQLQ)。此外,我们估计了最重要的差异(中期)。基于所述哮喘控制测试(ACT)的分数,我们定义了三组:(?ACT> 19)(?14

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号